Transcription of 重症筋無力症(Myasthenia gravis:MG)
{{id}} {{{paragraph}}}
( myasthenia gravis :MG).. 1/74.. The Cochrane database MEDLINE . Agency for Health Care Policy and Research AHCPR .. 2 . MG. PSL. AChR. 2/74.. 1.. 2.. 3.. 4.. 5.. 1.. 2.. 3.. 4.. 5.. 1.. 2.. 3.. 4.. 5.. 1.. 2.. 3.. 4.. 1. tacrolims hydrate (FK506 ). A.. B.. C.. D.. 2. azathioprine AZP . A.. B.. C.. D.. 3. ciclosporine (CYA ). A.. 3/74. B.. C.. D.. 4. cyclophosphamide (CPA ). A.. B.. C.. D.. 5. mycophenolate mofetil . A.. B.. C.. D.. 1.. 2.. 3.. A.. B. (double filtration plasmapheresis DFPP). C. (immuno absorption IA).. 1.. 2.. 3.. 4.. MG .. MG .. MG .. MG ..Sero-negative MG .. 4/74.. 1.. (ACh) . AChR T AChR . AChR . B T . MHC AChR . positive negative selection . [8] . AChR MG seronegative MG . [1] . 2.. 3.. 1 . AChR . seronegative MG .. 4.. Osserman 2 myasthenia gravis Foundation of America MGFA score 3 4 ADL 5 7.
Myasthenia gravis: pathogenesis and treatment. Tokyo: University of Tokyo Press. 1981;9-17 6) Araki S, Uchino M, Kumamoto T. Prevalence studies of multiple sclerosis, myasthenia gravis, and myopathies in Kumamoto district, Japan. Neuroepidemiology 1987; 6: 120-129 7) Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up ...
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}